The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIV.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Nishiyama Y, Omori S, Matsumoto H, Komiya K, Hiramatsu K

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer.

Internal medicine (Tokyo, Japan). 2023;62(23):3507-3510

Tereso A, Carreto L, Baptista M, Almeida MA

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer.

Acta medica portuguesa. 2019;32(3):236-239

Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, Houzawa H, Ueno N, Ohki E, Yoshimura A

Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019;14(4):672-682

Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.

ESMO open. 2017;2(3):e000219

Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, Stollenwerk NS

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.

Clinical lung cancer. 2017;18(5):472-479

Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(8):1148-55

Maka VV, Krishnaswamy UM, Anil Kumar N, Chitrapur R, Kilara N

Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy.

Oxford medical case reports. 2014;2014(1):11-2

Asai N, Yamaguchi E, Kubo A

Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.

Clinical lung cancer. 2014;15(3):e33-5

Rothenstein JM, Letarte N

Managing treatment-related adverse events associated with Alk inhibitors.

Current oncology (Toronto, Ont.). 2014;21(1):19-26

Watanabe N, Nakahara Y, Taniguchi H, Kimura T, Kondoh Y, Kataoka K, Sakamoto K

Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.

Acta oncologica (Stockholm, Sweden). 2014;53(1):158-60

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

The New England journal of medicine. 2013;368(25):2385-94

Jett JR, Carr LL

Targeted therapy for non-small cell lung cancer.

American journal of respiratory and critical care medicine. 2013;188(8):907-12

Timm A, Kolesar JM

Crizotinib for the treatment of non-small-cell lung cancer.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013;70(11):943-7

Ou SH

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Drug design, development and therapy. 2011;5:471-85

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J,

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

The New England journal of medicine. 2010;363(18):1693-703